Advisory Committees: US FDA Should Explain Divergent Decisions But Keep The Vote

 
• By Sue Sutter
  
Diverging paths
FDA should publicly explain why it made a regulatory decision that diverged from adcomm advice, stakeholders said. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers